[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595724":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":27,"responsibleParty":45,"collaborators":11,"id":47,"slug":11,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":11,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":11,"overallStatus":30,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HDM1702","EXPERIMENTAL",null,[13],"Drug: HDM1702",{"label":15,"type":16,"description":11,"interventionNames":17},"WEGOVY®","ACTIVE_COMPARATOR",[18],"Drug: Wegovy ®",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Initiate at a once weekly dose of 0.25 mg and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg per week) aiming at reaching the maintenance dose of 2.4 mg at week 16.",[9],{"type":21,"name":25,"description":22,"armGroupLabels":26,"otherNames":11},"Wegovy ®",[15],[28],{"facility":29,"status":30,"city":31,"state":11,"zip":11,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Peking University People's Hospital","RECRUITING","Beijing","China",{"type":34,"coordinates":35},"Point",[36,37],116.39723,39.9075,{"lat":37,"lon":36},[40],{"name":41,"role":42,"phone":43,"phoneExt":11,"email":44},"Linong Ji, Medical Doctor","CONTACT","+8601088324516","jiln@bjmu.edu.cn",{"type":46,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100595724",false,"NCT07036172","Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients","A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Clinical Study Comparing the Efficacy and Safety of Semaglutide Injection and WEGOVY® in Chinese Obese Patients","Inclusion Criteria:\n\n1. Male or female, aged ≥18 years and ≤75 years at the time of signing informed consent；\n2. BMI ≥28 kg\u002Fm2；\n3. A self-reported change in body weight no more than 5% within 90 days before screening.\n\nExclusion Criteria:\n\n1. History of type 1 and type 2 diabetes;\n2. Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device;\n3. History or presence of chronic or acute pancreatitis;\n4. Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma;\n5. A history or presence of suspected depression or other mental disorders;\n6. Patient Health Questionnaire-9 score of ≥15 at screening\n7. Uncontrolled hypertension, any of the following: myocardial infarction, stroke, hospitalisation for unstable angina, or transient ischaemic attack within the past 6 months prior to screening;\n8. History of malignant neoplasms within the past 5 years prior to screening;","ALL","18 Years","75 Years",{"count":57,"type":58},460,"ESTIMATED","INTERVENTIONAL",[61],"PHASE3","This is a 48-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and WEGOVY® in patients with obesity. Eligible participants will be screened and randomized to the experimental group and the active comparator group at a ratio of 1:1 , semaglutide injection or WEGOVY® injection will be given once weekly for 44 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.",[64],"Obesity Control","2025-06-16",{"date":67,"type":68},"2025-06-25","ACTUAL",{"date":70,"type":68},"2025-01-03",{"date":72,"type":58},"2026-05",{"name":5,"class":6},1]